Pier Francesco Ferrucci

Pier Francesco Ferrucci is an oncologist with clinical and translational expertise in Phase I trials of novel immunotherapy agents, including anti-CD47 innate immune checkpoint antibodies. He has contributed to early clinical investigation of magrolimab (anti-CD47) and studied the combination of CD47 blockade with PD-1/PD-L1 inhibitors in solid tumors. His work addresses the role of macrophage phagocytosis in anti-tumor immunity and how innate immune checkpoints can be leveraged in combination with adaptive checkpoint blockade. He contributes to the European Phase I oncology research network.